Exagen Inc. XGN Reportable Segment — Cost of revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Exagen Inc. in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The official record: Exagen Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Exagen Inc.'s reportable segment — cost of revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Exagen Inc.'s reportable segment — cost of revenue?
- Exagen Inc. (XGN) reported reportable segment — cost of revenue of $7.1M in Q1 2026.
- How has Exagen Inc.'s reportable segment — cost of revenue changed year-over-year?
- Exagen Inc.'s reportable segment — cost of revenue increased by 11.4% year-over-year, from $6.38M to $7.1M.
- What is the long-term trend for Exagen Inc.'s reportable segment — cost of revenue?
- Over 2 years (2023 to 2025), Exagen Inc.'s reportable segment — cost of revenue has grown at a 9.7% compound annual growth rate (CAGR), from $23.09M to $27.78M.
- What does reportable segment — cost of revenue mean?
- The direct costs incurred to produce and deliver the diagnostic tests sold by the segment, including laboratory materials, reagents, and direct labor. Monitoring this metric is essential for evaluating the segment's production efficiency and direct margin management.